The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
Hyaluronic acid is among the world's most valuable biopolymers, with applications spanning from dermal fillers and wound healing to drug delivery and tissue engineering
New site expands manufacturing footprint to meet future demand; ensures continued on-time delivery rate of >99.9% to patients across western US, Alaska and Hawaii
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Poviztra is a second brand of Wegovy
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Subscribe To Our Newsletter & Stay Updated
